Abstract
This work was supported by National Institute on Aging Grants P01 AG03991 and P50 AG05681. Disclosure: Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. Since July 2003, Dr. Morris participated or is currently participating in clinical trials of anti-dementia drugs sponsored by Elan, Eli Lilly and Company, Merck, and Wyeth. In 2003 and 2004, Dr. Morris served as a consultant for or received speaking honoraria from the following companies: Amgen, Axonyx, BristolMyersSquibb, Codman-Johnson & Johnson, Eisai, Elan, Forest Labs, Neurochem, Novartis, Sanofi-Aventis, and Shionogi-Glaxo-Smith-Kline. Reprints: John C. Morris, MD, Friedman Distinguished Professor of Neurology Alzheimer's Disease Research Center, Washington University, 4488 Forest Park, Suite 130, St. Louis, MO 63108 (e-mail: [email protected]).
Keywords
DementiaGerontologyMedicineManagementFamily medicineLibrary sciencePsychologyDiseaseInternal medicineComputer science
Related Publications
Diagnosis and management of dementia with Lewy bodies
The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical featur...
2018 Alzheimer's disease facts and figures
Abstract This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, costs of care, and the overall...
Donanemab in Early Symptomatic Alzheimer Disease
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyl...
Alzheimer disease
Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neu...
Publication Info
- Year
- 2005
- Type
- article
- Volume
- 19
- Issue
- 3
- Pages
- 163-165
- Citations
- 188
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
188
OpenAlex
Cite This
NULL AUTHOR_ID
(2005).
Early-Stage and Preclinical Alzheimer Disease.
Alzheimer Disease & Associated Disorders
, 19
(3)
, 163-165.
https://doi.org/10.1097/01.wad.0000184005.22611.cc
Identifiers
- DOI
- 10.1097/01.wad.0000184005.22611.cc